Asthma causes inflammation and narrowing of the airways, making it harder to breathe. Symptoms may include wheezing, coughing, chest tightness, and shortness of breath. These symptoms can vary in ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

LONDON, Dec 16 (Reuters) - The U.S. health regulator has approved GSK's (GSK.L), opens new tab add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won European regulatory approval for two inflammatory disease indications. The European Medicines Agency's ...

Asthma care continues to develop, particularly in how treatment and long-term management are approached. This article outlines current treatment and management recommendations for patients aged 12 and ...

People with severe asthma sometimes rely on daily steroid pills, which raise the risk of diabetes, infections and bone problems. Now, a study supports the idea that a monthly antibody injection is a ...

An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. The drug dupilumab (Dupixent) effectively clears up airways ...

Lennis Mitchell died in custody after telling Lafayette police he couldn't breathe and had asthma. An autopsy is pending to determine if Mitchell's death was caused by an asthma attack or other ...

A groundbreaking international study has shown that a 2-in-1 budesonide-formoterol inhaler is far more effective than the standard salbutamol inhaler in children with mild asthma, cutting attacks by ...

Inhalers that combine providing immediate relief with a longer-term preventative effect are already recommended as the standard treatment for mild asthma among people aged 12 and above in the UK, US ...